709665-73-6

Usage

Uses

Used in Organic Synthesis:
(4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester is used as a building block in organic synthesis for the preparation of complex organic molecules. Its unique structure allows for the creation of a variety of compounds with diverse applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester is used as a precursor for the synthesis of various pharmaceuticals. Its presence in the molecular structure of potential drugs can contribute to their therapeutic effects and properties.
Used in Agrochemical Industry:
(4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester is also used as a precursor in the synthesis of agrochemicals, where it can be incorporated into the molecular structure of compounds designed to protect crops and enhance agricultural productivity.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (4-Bromophenyl)-tert-butoxycarbonylaminoacetic acid methyl ester is used as a potential lead compound for the development of new drugs. Its unique chemical properties make it a valuable candidate for further exploration and optimization in drug discovery processes.

InChI:InChI=1/C14H18BrNO4/c1-13(2,3)20-12(18)14(16,11(17)19-4)9-5-7-10(15)8-6-9/h5-8H,16H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 42718-15-0 methyl 2-amino-2-(4-bromophenyl)acetate 
• 119397-06-7 2-amino-2-(4-bromophenyl)acetic acid 
• 917925-71-4 2-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)acetic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 369403-44-1 2-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)acetic acid 

Relevant academic research and scientific papers

A Structure?Activity Relationship Study of Novel Hydroxamic Acid Inhibitors around the S1 Subsite of Human Aminopeptidase N

Aminopeptidase N (APN/CD13) is a zinc-dependent ubiquitous transmembrane ectoenzyme that is widely present in different types of cells. APN is one of the most extensively studied metalloaminopeptidases as an anti-cancer target due to its significant role in the regulation of metastasis and angiogenesis. Previously, we identified a potent and selective APN inhibitor, N-(2-(Hydroxyamino)-2-oxo-1-(3′,4′,5′-trifluoro-[1,1′-biphenyl]-4-yl)ethyl)-4-(methylsulfonamido)benzamide (3). Herein, we report the further modifications performed to explore SAR around the S1 subsite of APN and to improve the physicochemical properties. A series of hydroxamic acid analogues were synthesised, and the pharmacological activities were evaluated in vitro. N-(1-(3′-Fluoro-[1,1′-biphenyl]-4-yl)-2-(hydroxyamino)-2-oxoethyl)-4-(methylsulfonamido)benzamide (6 f) was found to display an extremely potent inhibitory activity in the sub-nanomolar range.

Dihydropyridine compound and application thereof to drugs

The invention relates to a dihydropyridine compound and application of the dihydropyridine compound serving as a drug, in particular to application of the dihydropyridine compound serving as a drug for treating and preventing hepatitis B. Specifically, the invention relates to the compound shown as the general formula (I) or (Ia) (please see the specifications for the general formula (I) or (Ia))or stereoisomers, tautomer, a nitrogen oxide, solvate, metabolites and medically acceptable salt of the compound or a prodrug of the compound, wherein all variables are defined in the specification. The invention further relates to application of the compound shown as the general formula (I) or (Ia) or enantiomers, non-enantiomers, the tautomer, hydrates, the solvate or the medically acceptable salt of the compound serving as drugs, in particular to application of the compound or the enantiomers, the non-enantiomers, the tautomer, the hydrates, the solvate or the medically acceptable salt of the compound serving as the drugs for treating and preventing hepatitis B.

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

NOVEL AMINOPEPTIDASE INHIBITORS AND METHODS OF USE

An aminopeptidase inhibitor compound comprising a biaryl, hydroxamic acid based core of formula: wherein X is a 5 or 6-membered ring, and including pharmaceutically acceptable salts and solvates thereof.

Potent dual inhibitors of Plasmodium falciparum M1 and M17 aminopeptidases through optimization of S1 pocket interactions

Malaria remains a global health problem, and though international efforts for treatment and eradication have made some headway, the emergence of drug-resistant parasites threatens this progress. Antimalarial therapeutics acting via novel mechanisms are urgently required. Plasmodium falciparum M1 and M17 are neutral aminopeptidases which are essential for parasite growth and development. Previous work in our group has identified inhibitors capable of dual inhibition of PfA-M1 and PfA-M17, and revealed further regions within the protease S1 pockets that could be exploited in the development of ligands with improved inhibitory activity. Herein, we report the structure-based design and synthesis of novel hydroxamic acid analogues that are capable of potent inhibition of both PfA-M1 and PfA-M17. Furthermore, the developed compounds potently inhibit Pf growth in culture, including the multi-drug resistant strain Dd2. The ongoing development of dual PfA-M1/PfA-M17 inhibitors continues to be an attractive strategy for the design of novel antimalarial therapeutics.

AMIDE DERIVATIVES AS KINASE INHIBITORS

The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer, tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar1, Ar2, R1, R3, p and n have the meaning defined in the claims. In particular, the present invention relates to more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.